Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of ImmuNext Inc.

    Client Virtual Booth

    IMMUNEXT INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ImmuNext Inc
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Medical Center Drive Lebanon, NH 03756
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.immunext.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/immunext
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

    Details:

    Through the acquisition, Royalty pharma gains royalties and milestones on SAR441344 (frexalimab), a first-in-class, second generation anti-CD40 ligand monoclonal antibody, for the treatment of multiple sclerosis.


    Lead Product(s): Frexalimab

    Therapeutic Area: Neurology Product Name: SAR441344

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Royalty Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition May 09, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies n-

    Details:

    ImmuNext will develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext's lead compound, CI-8993 (formerly JNJ-61610588).


    Lead Product(s): Onvatilimab

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Curis

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 07, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search